(Q46158244)

20 December 2017

title

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up (English)

1 reference

20 December 2017

1 reference

1 reference

1 reference

P-C Wu

1

1 reference

20 December 2017

Y-J Chen

series ordinal

2

1 reference

20 December 2017

publication date

16 January 2009

1 reference

20 December 2017

published in

Eye

1 reference

20 December 2017

volume

23

1 reference

20 December 2017

issue

11

1 reference

20 December 2017

page(s)

2042-2045

1 reference

20 December 2017

Etiology of choroidal neovascularization in young patients

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.404

Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.404

7 January 2021

Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.404

7 January 2021

Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.404

7 January 2021

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.404

7 January 2021

Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.404

7 January 2021

Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.404

7 January 2021

Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.404

7 January 2021

Identifiers

DOI

10.1038/EYE.2008.404

1 reference

20 December 2017

1 reference

20 December 2017